Amgen Inc.
MODULATING ANTIBODY EFFECTOR FUNCTIONS

Abstract:

Provided herein are methods of modulating Fc gamma Receptor (Fc.gamma.R)-mediated cytotoxicity of an antibody composition. In exemplary embodiments, the method comprises (1) increasing or decreasing the amount of terminal .beta.-galactose at the N-297 glycosylation site of panitumumab, or increasing or decreasing the amount of panitumumab molecules that comprise G1, G1a, G1b and/or G2 galactosylated glycan at the N-297 site, (2) increasing or decreasing the amount of panitumumab molecules that comprise fucosylated glycan at the N-297 site, or increasing or decreasing the amount of panitumumab molecules that comprise afucosylated glycan at the N-297 site, and (3) increasing or decreasing the amount of panitumumab molecules that comprise a high-mannose glycan at the N-297 site.